|
Jenkins, Samir V; Nedosekin, Dmitry A; Miller, Emily K et al. (2018) Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy. Int J Hyperthermia 34:19-29
|
|
Koonce, Nathan A; Juratli, Mazen A; Cai, Chengzhong et al. (2017) Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry. Biochem Biophys Res Commun 492:507-512
|
|
Song, Chang W; Lee, Yoon-Jin; Griffin, Robert J et al. (2015) Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery. Int J Radiat Oncol Biol Phys 93:166-72
|
|
Koonce, Nathan A; Quick, Charles M; Hardee, Matthew E et al. (2015) Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-? and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models. Int J Radiat Oncol Biol Phys 93:588-96
|
|
Koonce, Nathan A; Levy, Joseph; Hardee, Matthew E et al. (2015) Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia. PLoS One 10:e0135607
|
|
Przybyla, Beata D; Shafirstein, Gal; Vishal, Sagar J et al. (2014) Molecular changes in bone marrow, tumor and serum after conductive ablation of murine 4T1 breast carcinoma. Int J Oncol 44:600-8
|
|
Shao, Jingwei; Griffin, Robert J; Galanzha, Ekaterina I et al. (2013) Photothermal nanodrugs: potential of TNF-gold nanospheres for cancer theranostics. Sci Rep 3:1293
|
|
Upreti, Meenakshi; Jamshidi-Parsian, Azemat; Apana, Scott et al. (2013) Radiation-induced galectin-1 by endothelial cells: a promising molecular target for preferential drug delivery to the tumor vasculature. J Mol Med (Berl) 91:497-506
|
|
Barnes, Klressa D; Shafirstein, Gal; Webber, Jessica S et al. (2013) Hyperthermia-enhanced indocyanine green delivery for laser-induced thermal ablation of carcinomas. Int J Hyperthermia 29:474-9
|
|
Kim, Jin-Woo; Galanzha, Ekaterina I; Zaharoff, David A et al. (2013) Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo. Mol Pharm 10:813-30
|
Showing the most recent 10 out of 103 publications
